Alpha Profiles · Company Profile

Inventiva S.A.

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics.

https://registry.alpha.ac/companies/inventiva-s-a

Entity: Public listing published
Primary listing: NASDAQ: IVA
Verification: Partially verified
Last reviewed: 2026-10-23T04:48:42.447898+00:00

Overview

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH.

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 23, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

0 public records

Board roster coverage is NOT_ASSERTED. An empty list is not evidence that this company has no board.

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-10-23T04:48:42.447898+00:00